HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 29 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $17,000 | -37.0% | 51,498 | +36.1% | 0.00% | – |
| Q2 2020 | $27,000 | +2600.0% | 37,840 | +1277.0% | 0.00% | – |
| Q1 2020 | $1,000 | -50.0% | 2,748 | -14.1% | 0.00% | – |
| Q4 2019 | $2,000 | -98.6% | 3,199 | -94.4% | 0.00% | – |
| Q1 2019 | $144,000 | -10.0% | 57,470 | -8.6% | 0.00% | – |
| Q4 2018 | $160,000 | -66.0% | 62,872 | -32.3% | 0.00% | – |
| Q3 2018 | $470,000 | +120.7% | 92,936 | +41.9% | 0.00% | – |
| Q2 2018 | $213,000 | -25.5% | 65,510 | -17.0% | 0.00% | – |
| Q1 2018 | $286,000 | +1091.7% | 78,970 | +566.1% | 0.00% | – |
| Q4 2017 | $24,000 | +33.3% | 11,855 | +13.0% | 0.00% | – |
| Q3 2017 | $18,000 | +100.0% | 10,490 | +216.7% | 0.00% | – |
| Q2 2017 | $9,000 | – | 3,312 | +27500.0% | 0.00% | – |
| Q1 2016 | $0 | – | 12 | 0.0% | 0.00% | – |
| Q4 2015 | $0 | -100.0% | 12 | -99.4% | 0.00% | – |
| Q2 2015 | $21,000 | – | 1,886 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| PERKINS CAPITAL MANAGEMENT INC | 2,426,300 | $802,000 | 0.74% |
| Cowen Prime Services LLC | 1,411,500 | $466,000 | 0.23% |
| GSA CAPITAL PARTNERS LLP | 1,205,873 | $398,000 | 0.07% |
| Nantahala Capital Management | 5,113,958 | $1,690,000 | 0.05% |
| HighMark Wealth Management LLC | 80,000 | $26,000 | 0.02% |
| Kalos Management, Inc. | 72,858 | $24,000 | 0.01% |
| Qube Research & Technologies Ltd | 585,187 | $193,000 | 0.00% |
| WINTON GROUP Ltd | 190,146 | $63,000 | 0.00% |
| Ironwood Financial, llc | 1,571 | $1,000 | 0.00% |
| Virtu Financial LLC | 12,049 | $4,000 | 0.00% |